A Phase I Trial of Zevalin Radioimmunotherapy with High-Dose Melphalan (HDM) and Autologous Stem Cell Transplant (ASCT) for Multiple Myeloma (MM)

被引：1
|
作者：
Dispenzieri, Angela
Gertz, Morie Abraham [1 ]
Lacy, Martha Q.
Laumann, Kristina [2 ]
LaPlant, Betsy R.
Kumar, Shaji [1 ]
Buadi, Francis K.
Hayman, Suzanne R. [1 ]
Dingli, David
Hogan, William J.
Ansell, Stephen M. [1 ]
Gastineau, Dennis A.
Inwards, David James [1 ]
Micallef, Ivana N. [1 ]
Porrata, Luis F. [1 ]
Johnston, Patrick B. [1 ]
Litzow, Mark R. [1 ]
Witzig, Thomas E. [1 ]
机构：
[1] Mayo Clin, Div Hematol, Dept Internal Med, Rochester, MN USA
[2] Mayo Clin, Canc Ctr Stat, Rochester, MN USA
来源：
BLOOD | 2011年 / 118卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1337 / 1338
页数：2
相关论文
共 50 条
  • [1] TIMING OF HIGH DOSE MELPHALAN (HDM) AND OUTCOMES FOR AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) IN PATIENTS WITH MULTIPLE MYELOMA (MM)
    Mahindra, A.
    Bolwell, B.
    Rybicki, L.
    Sobecks, R.
    Pohlman, B.
    Andresen, S.
    Earl, M.
    Dean, R.
    Copelan, E.
    Kalaycio, M.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2009, 15 (02) : 41 - 42
  • [2] Salvage bortezomib–dexamethasone and high-dose melphalan (HDM) and autologous stem cell support (ASCT) in myeloma patients at first relapse after HDM with ASCT. A phase-2 trial
    P Gimsing
    Ø Hjertner
    N Abildgaard
    N F Andersen
    T G Dahl
    H Gregersen
    T W Klausen
    U-H Mellqvist
    O Linder
    R Lindås
    N Tøffner Clausen
    S Lenhoff
    Bone Marrow Transplantation, 2015, 50 : 1306 - 1311
  • [3] A phase 1 trial of 90Y-Zevalin radioimmunotherapy with autologous stem cell transplant for multiple myeloma
    Dispenzieri, A.
    D'Souza, A.
    Gertz, M. A.
    Laumann, K.
    Wiseman, G.
    Lacy, M. Q.
    LaPlant, B.
    Buadi, F.
    Hayman, S. R.
    Kumar, S. K.
    Dingli, D.
    Hogan, W. J.
    Ansell, S. M.
    Gastineau, D. A.
    Inwards, D. J.
    Micallef, I. N.
    Porrata, L. F.
    Johnston, P. B.
    Litzow, M. R.
    Witzig, T. E.
    BONE MARROW TRANSPLANTATION, 2017, 52 (10) : 1372 - 1377
  • [4] A phase 1 trial of 90Y-Zevalin radioimmunotherapy with autologous stem cell transplant for multiple myeloma
    A Dispenzieri
    A D'Souza
    M A Gertz
    K Laumann
    G Wiseman
    M Q Lacy
    B LaPlant
    F Buadi
    S R Hayman
    S K Kumar
    D Dingli
    W J Hogan
    S M Ansell
    D A Gastineau
    D J Inwards
    I N Micallef
    L F Porrata
    P B Johnston
    M R Litzow
    T E Witzig
    Bone Marrow Transplantation, 2017, 52 : 1372 - 1377
  • [5] Salvage bortezomib-dexamethasone and high-dose melphalan (HDM) and autologous stem cell support (ASCT) in myeloma patients at first relapse after HDM with ASCT. A phase-2 trial
    Gimsing, P.
    Hjertner, O.
    Abildgaard, N.
    Andersen, N. F.
    Dahl, T. G.
    Gregersen, H.
    Klausen, T. W.
    Mellqvist, U-H
    Linder, O.
    Lindas, R.
    Clausen, N. Toffner
    Lenhoff, S.
    BONE MARROW TRANSPLANTATION, 2015, 50 (10) : 1306 - 1311
  • [6] Thalidomide (HAL) maintenance following high-dose melphalan with autologous stem cell transplant (ASCT) for myeloma.
    Chang, Julie E.
    Juckett, Mark B.
    Kahl, Brad. S.
    Mitchell, Teri L.
    Gangnon, Ronald E.
    Callander, Natalie S.
    Longo, Walter L.
    BLOOD, 2006, 108 (11) : 459B - 459B
  • [7] ASCT and high-dose melphalan in multiple myeloma
    Sharma, Sharan Prakash
    LANCET ONCOLOGY, 2014, 15 (11): : E481 - E481
  • [8] A Phase I Trial of High-Dose Lenalidomide and Melphalan as Conditioning for Autologous Stem Cell Transplantation in Relapsed or Refractory Multiple Myeloma
    Mark, Tomer M.
    Guarneii, Danielle
    Forsberg, Peter
    Rossi, Adriana
    Pearse, Roger
    Perry, Arthur
    Pekle, Karen
    Tegnestam, Linda
    Greenberg, June
    Shore, Tsiporah
    Gergis, Usama
    Mayer, Sebastian
    Van Besien, Koen
    Ely, Scott
    Jayabalan, David
    Sherbenou, Daniel
    Coleman, Morton
    Niesvizky, Ruben
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2017, 23 (06) : 930 - 937
  • [9] Phase II trial of high-dose topotecan, melphalan and CY with autologous stem cell support for multiple myeloma
    S M A Kazmi
    R M Saliba
    M Donato
    M Wang
    C Hosing
    S Qureshi
    P Anderlini
    U Popat
    R E Champlin
    S A Giralt
    M H Qazilbash
    Bone Marrow Transplantation, 2011, 46 : 510 - 515
  • [10] Phase II trial of high-dose topotecan, melphalan and CY with autologous stem cell support for multiple myeloma
    Kazmi, S. M. A.
    Saliba, R. M.
    Donato, M.
    Wang, M.
    Hosing, C.
    Qureshi, S.
    Anderlini, P.
    Popat, U.
    Champlin, R. E.
    Giralt, S. A.
    Qazilbash, M. H.
    BONE MARROW TRANSPLANTATION, 2011, 46 (04) : 510 - 515
12345